FORIMMEDIATERELEASE

REVATENPLATELETRICHPLASMASHOWSPROMISEASPOTENTIAL
TREATMENTFORHEARTATTACKS
STANFORD,Calif.ResearchersattheStanfordUniversitySchoolofMedicine,in
collaborationwithBioParadox,Inc.,havepublisheddatasupportingtheuseofplatelet
richplasmaasapromisingbiologictreatmentformyocardialinfarction(heartattack).
ThefindingswerepublishedonlineinCardiovascularRevascularizationMedicineand
willbepresentedatTheSixthInternationalConferenceonCellTherapyfor
CardiovascularDiseaseatColumbiaUniversityMedicalCenter,NewYorkCity,on
January20,2011.
Plateletrichplasma(PRP)hasbeenidentifiedasanovelbiologictreatmentforwound
healingandsportsrelatedinjuries.StudiesindicatePRPstimulatescellrepairviagrowth
factorreleaseandbyattractingreparativecells.Onlyrecently,however,havescientists
beguntostudyPRPspotentialinrepairingdamagedcardiovasculartissue.
WorkingwithcolleaguesatStanfordUniversityMedicalCenter,leadauthorAllan
Mishra,MD,aleadingPRPresearcher,studiedtheeffectsofRevaTenPRP(aproprietary
formulationofconcentratedplateletsandwhitebloodcells)oncardiacfunctionafter
inducingcardiacischemia(damagetomyocardialtissuecausedbybloodrestriction)in
mice.TheresearchwasconductedunderthedirectionofRobertRobbins,MD,chairman
ofthedepartmentofcardiothoracicsurgeryatStanfordUniversity.
Inthisstudyof28mice,researchersinducedischemiabyeitherpermanentlyoccluding
theleftanteriordescendingartery(GroupA)ortemporarilyligatingitfor45minutes
(GroupB).TheheartsweretheninjectedwithRevaTenPRPorsalinecontrol.Inorderto
assesscardiacfunctionaftertreatment,magneticresonanceimagesweretakenatseven
dayspostprocedure(GroupA)and21days(GroupB).Tissuefromallheartswas
collectedforhistopathologicevaluation.
Inbothgroups,micethatreceivedPRPafterischemiahadsignificantlybettercardiac
functionasmeasuredbyleftventricularejectionfractiononMRIthanthosethathadbeen
injectedwithsalineonly.IngroupA,theRevaTentreatedanimalshad38%better
ejectionfractioncomparedtosalinecontrols.IngroupB,theRevaTentreatedanimals
had28%improvementinejectionfractioncomparedtocontrols.Additionally,lessscar
tissuewasfoundinRevaTentreatedheartsthanincontrols.
Althoughthisisanobservationalstudyusingananimalmodel,PRPmightsomedaybe
employedatthepointofcaretotreatpatientswhohavehadaheartattack.Thiscould
preservecardiacfunctionandlimittheprogressiontocongestiveheartfailure,Dr.
Mishrasays.Sincemyocardialinfarctionremainstheleadingcauseofdeathin

more
industrialnations,RevaTenPRPmaybecomeapowerfulbiologictoolinfightingheart
diseaseandprovidecostsavings.Theauthorscautionthatthisisapreclinicalstudyand
thatfurthertranslationalresearchisneededtounderstandhowRevaTenPRPmightwork
torepairand/orprotectcardiovasculartissue.

###
Disclosure:TheresearchwasfundedbyBioParadox,Inc.,MenloPark,CA.Some
authorsofthispaperareaffiliatedwithBioParadox,Inc.(www.bioparadox.com).The
companyisinnovatinguseofPlateletCellTherapyTMforthetreatmentofcardiovascular
disease.Pleaserefertothepaperforcompletedisclosures.
InformationonTheSixthInternationalConferenceonCellTherapyforCardiovascular
Diseaseisavailableathttp://celltherapy.crf.org.
Mediainquiries:PattiDavis,MPH,DAVISMEDPR,Inc.,Chicago,Ill.,(630)9208042.